Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative
approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non …

This review highlights literature pertinent to chimerism analysis in the context of
hematopoietic cell transplantation (HCT). We also conducted a survey of testing practices of …

We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning
in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients …

Background aims The value of routine chimerism determination after myeloablative
hematopoietic cell transplantation (HCT) is unclear, particularly in the setting of anti …

We evaluated long-term outcome in 40 patients with MDS or AML, transplanted from related
or unrelated donors following conditioning with targeted busulfan (Bu, over 4 days) …

Transplantation of allogeneic hematopoietic cells faces two barriers: failure of engraftment
due to a host versus graft reaction, and the attack of donor cells against the patient, the graft …

Introduction This longitudinal study was based on the outcomes of Donor Lymphocyte
Infusion (DLI) for falling peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) …

Allogeneic hematopoeitic cell transplantation (allo‐HCT) is the only curative treatment for
myelofibrosis (MF). We evaluate the impact of various factors on survival outcomes post …

In patients who have undergone allogeneic hematopoietic cell transplantation (HCT),
myeloid mixed donor chimerism (MC) is a risk factor for disease relapse. In contrast, several …

Трансплантация аллогенных гемопоэтических стволовых клеток является одним из
эффективных методовлечения пациентов с заболеваниями системы крови. Среди …